This is an aggregated industry headline. Read the full story at FierceBiotech →
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for its dystrophy prospect.
By FierceBiotech
· Jun 12, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is strugglin…
The WeekFierceBiotech ↗
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease …
The WeekBriefing
Nuvalent’s Jideytro won FDA approval for adults with locally advanced or metastatic ROS1-positive NSCLC after …